Anti-L1CAM antibody: A novel efficacious immunotherapy for pancreatic and ovarian cancer patients

Project description

Inhibiting cellular 'stickiness' could cure pancreatic and ovarian cancers

Fields of science

• natural sciences › biological sciences › cell biology
• medical and health sciences › clinical medicine › oncology › colorectal cancer
• medical and health sciences › basic medicine › immunology › immunotherapy
• medical and health sciences › clinical medicine › oncology › pancreatic cancer
• medical and health sciences › basic medicine › toxicology

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

ELTHERA AG

Net EU contribution

€ 2 495 176,25

Address

Brandstrasse 24
8952 Schlieren
Switzerland

Region

Schweiz/Suisse/Svizzera › Zürich › Zürich

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Non-EU contribution

€ 1 756 236,25